{
  "id": 1443510,
  "title": "AstraZeneca To Cease EVOLVE-Lung02 Phase III Trial Of Volrustomig + Chemotherapy In MNSCLC",
  "url": "https://urgent.news/2026/08/17/astrazeneca-to-cease-evolve-lung02-phase-iii-trial-of-volrustomig",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T06:58:53.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/astrazeneca-cease-evolve-lung02-phase-iii-trial-volrustomig-chemotherapy-mnsclc"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer or mNSCLC, based on the recommendation of the Independent Data Monitor",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}